Hepatitis E vaccine development A 14-year odyssey
- 公共卫生－已发表论文 
The first prophylactic vaccine, Hecolin (R), against hepatitis E virus (HEV) infection and the HEV associated disease was approved by China State Food and Drug Administration (SFDA) in December 2011. Key milestones during the 14-year HEV vaccine development are summarized in this short report. After years' innovative research, the recombinant virus-like particle (VLP) based antigen with virion-like epitopes was successfully produced in E. coli production platform at commercial scale. Safety and efficacy of this vaccine was demonstrated in a large scale Phase III clinical trial.
CitationHUMAN VACCINES & IMMUNOTHERAPEUTICS，2012,8（6）：823-827